AU2016206693A1 - Synthesis of a Bruton's tyrosine kinase inhibitor - Google Patents

Synthesis of a Bruton's tyrosine kinase inhibitor Download PDF

Info

Publication number
AU2016206693A1
AU2016206693A1 AU2016206693A AU2016206693A AU2016206693A1 AU 2016206693 A1 AU2016206693 A1 AU 2016206693A1 AU 2016206693 A AU2016206693 A AU 2016206693A AU 2016206693 A AU2016206693 A AU 2016206693A AU 2016206693 A1 AU2016206693 A1 AU 2016206693A1
Authority
AU
Australia
Prior art keywords
formula
compound
ibrutinib
amino
prop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016206693A
Other languages
English (en)
Inventor
Cyril BENHAIM
Wei Chen
Erick Goldman
Andras Horvath
Philip Pye
Mark S. Smyth
Erik J. Verner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Pharmacyclics LLC
Original Assignee
Janssen Pharmaceutica NV
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Pharmacyclics LLC filed Critical Janssen Pharmaceutica NV
Publication of AU2016206693A1 publication Critical patent/AU2016206693A1/en
Priority to AU2020230323A priority Critical patent/AU2020230323A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016206693A 2015-01-14 2016-01-14 Synthesis of a Bruton's tyrosine kinase inhibitor Abandoned AU2016206693A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020230323A AU2020230323A1 (en) 2015-01-14 2020-09-11 Synthesis of a Bruton's tyrosine kinase inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020230323A Division AU2020230323A1 (en) 2015-01-14 2020-09-11 Synthesis of a Bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
AU2016206693A1 true AU2016206693A1 (en) 2017-07-13

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016206693A Abandoned AU2016206693A1 (en) 2015-01-14 2016-01-14 Synthesis of a Bruton's tyrosine kinase inhibitor
AU2020230323A Abandoned AU2020230323A1 (en) 2015-01-14 2020-09-11 Synthesis of a Bruton's tyrosine kinase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020230323A Abandoned AU2020230323A1 (en) 2015-01-14 2020-09-11 Synthesis of a Bruton's tyrosine kinase inhibitor

Country Status (16)

Country Link
US (6) US20180009814A1 (enExample)
EP (1) EP3245208A4 (enExample)
JP (2) JP2018502077A (enExample)
KR (1) KR20170102887A (enExample)
CN (2) CN107108640A (enExample)
AU (2) AU2016206693A1 (enExample)
BR (1) BR112017015206B1 (enExample)
CA (2) CA2971460C (enExample)
HK (1) HK1246293A1 (enExample)
IL (4) IL322449A (enExample)
MA (1) MA41350A (enExample)
MX (2) MX366827B (enExample)
RU (1) RU2017128308A (enExample)
SG (2) SG11201705678YA (enExample)
WO (1) WO2016115356A1 (enExample)
ZA (1) ZA201704338B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712440C2 (ru) * 2015-02-12 2020-01-29 Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд Способ получения ибрутиниба
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
CN110944999A (zh) 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
JP6944496B2 (ja) 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
AU2018448845B2 (en) 2018-11-09 2022-03-24 Taiho Pharmaceutical Co., Ltd. Method for producing dimethoxybenzene compound
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
KR20220011669A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
JP7658916B2 (ja) * 2019-05-21 2025-04-08 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
EP2228369A1 (en) * 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2139487B1 (en) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Also Published As

Publication number Publication date
SG10201906517VA (en) 2019-08-27
CA2971460A1 (en) 2016-07-21
WO2016115356A1 (en) 2016-07-21
CN113816962A (zh) 2021-12-21
KR20170102887A (ko) 2017-09-12
MX2017009154A (es) 2017-10-12
BR112017015206A2 (pt) 2018-06-19
IL308276A (en) 2024-01-01
HK1246293A1 (zh) 2018-09-07
US20220098200A1 (en) 2022-03-31
CN107108640A (zh) 2017-08-29
US20180009814A1 (en) 2018-01-11
SG11201705678YA (en) 2017-08-30
CA3210320A1 (en) 2016-07-21
JP2021035947A (ja) 2021-03-04
CA2971460C (en) 2023-10-10
MA41350A (fr) 2017-11-21
EP3245208A4 (en) 2018-10-17
MX394327B (es) 2025-03-24
JP2018502077A (ja) 2018-01-25
BR112017015206B1 (pt) 2023-04-11
MX2019008815A (es) 2019-09-26
US20250197404A1 (en) 2025-06-19
ZA201704338B (en) 2023-10-25
US20200347064A1 (en) 2020-11-05
EP3245208A1 (en) 2017-11-22
US20190367518A1 (en) 2019-12-05
RU2017128308A3 (enExample) 2019-10-24
IL253020A0 (en) 2017-08-31
MX366827B (es) 2019-07-25
RU2017128308A (ru) 2019-02-14
IL322449A (en) 2025-09-01
AU2020230323A1 (en) 2020-10-01
US20240158400A1 (en) 2024-05-16
IL274716A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
US20240158400A1 (en) Synthesis of a bruton's tyrosine kinase inhibitor
TWI658042B (zh) 雜環化合物的合成
JP5831455B2 (ja) モルホリノ核酸誘導体
ES3056885T3 (en) Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
EP2794575B1 (en) Synthesis of triazolopyrimidine compounds
TW201825491A (zh) 製備細胞凋亡誘導劑的方法
KR20180008637A (ko) ｛1-(에틸술포닐)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일｝아세토니트릴의 제조를 위한 방법 및 중간체
WO2016014324A1 (en) Process for preparing chiral dipeptidyl peptidase-iv inhibitors
CN116897149A (zh) 一种连接基药物偶联物的制备方法及其中间体
KR20240129021A (ko) 1h-퓨로[3,2-b]이미다조[4,5-d]피리딘 화합물의 합성 방법
JP7809139B2 (ja) Ｂｔｋ阻害剤を調製するための方法
AU2019206560B2 (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
JP7025411B2 (ja) インドールカルボキサミド化合物の製造方法
TW202302605A (zh) 新穎方法
KR20160118359A (ko) 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조
WO2016071382A1 (en) Synthesis of pi3k inhibitor and salts thereof
EP4069687B1 (en) Process and intermediates for the production of formula (i)
CN109988172B (zh) 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
BR122022026564B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (ibrutinibe) e compostos
TW202419441A (zh) 烷基矽烷氧取代苄胺化合物之製造方法
CN101627041A (zh) 合成(3-烷基-5-哌啶-1-基-3,3a-二氢-吡唑并[1,5-a]嘧啶-7-基)-氨基衍生物和中间体的方法和中间体
PL223568B1 (pl) Tetrazolosulfanylowe pochodne alkaloidów drzewa chinowego oraz sposób ich wytwarzania
WO2021099554A1 (en) Process of preparing arachidonoylethanolamine analogues

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted